本帖最后由 老马 于 2012-1-13 21:20 编辑
/ V# ]+ \( v1 \$ i
" D8 j8 M' y3 J8 m$ O2 n爱必妥和阿瓦斯丁的比较
/ I. W3 t6 K! w; v: k# L
1 h: R# h ?6 H2 R; Jhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/3 V2 i* \% c5 B) h
; M; b3 P$ h( p, O) G' G
: @% Y- G/ W9 P' i1 b, N8 p
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
9 i+ J( N, l6 Z7 y8 z5 D6 [: H==================================================: G, B7 Z& D' G
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
9 x& B1 x) a2 O/ k1 j& qPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# O8 L8 I0 M3 D" t" q
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.- q$ S" L7 Q5 D6 f4 k" m% ?
|